0  -5%
Previous Close 0.40
Open 0.38
Price To book 19.05
Market Cap 78.49M
Shares 207,165,000
Volume 6,000
Short Ratio 0.00
Av. Daily Volume 42,552

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial failed to meet endpoints. Data released October 3, 2016.
Polymyxin B Hemoperfusion (PMX)
Endotoxemic septic shock

Latest News

  1. Spectral Medical, Inc. :EDTXF-US: Earnings Analysis: Q4, 2016 By the Numbers : April 6, 2017
  2. Spectral Voluntarily Delists From OTCQX
  3. Spectral Announces Appointment of Dr. Masayuki Kaneko to Its Board of Directors
  4. Spectral Medical, Inc. :EDTXF-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016
  5. Spectral Announces Next Steps in Path Forward and Issues Third Quarter Results
  6. Two Biotech Companies That Have Taken A Hit In The Past Week
  7. Spectral Medical's sepsis treatment fails late-stage study
  8. Spectral Responds to Recent Trading Activity
  9. Spectral Announces Participation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
  10. Spectral Unaware of Any Material Change
  11. Spectral on Track With Regulatory Pathway for Novel Septic Shock Treatment
  12. Spectral Announces Second Quarter Results
  13. Canada's Spectral hoping to win US approval for sepsis treatment
  14. Spectral Announces Normal Course Issuer Bid
  15. FDA Accepts Spectral's Expanded Access Protocol for Toraymyxin(TM)
  16. Spectral Medical, Inc. :EDTXF-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22, 2016
  17. Spectral Medical Announces Completion of Enrolment for Its Pivotal EUPHRATES Clinical Trial
  18. Spectral Medical Announces Acceptance of Pre-Clinical PMA Module for Toraymyxin(TM) by FDA
  19. Spectral Announces Voting Results of Annual Meeting
  20. Spectral Medical Files Expanded Access Protocol With FDA for Toraymyxin(TM) Septic Shock Treatment